Description

Overview

PT-141, also known as bremelanotide, is a synthetic melanocortin peptide that acts centrally on melanocortin receptors, particularly MC4R-related pathways. Unlike phosphodiesterase inhibitors, its principal research mechanism is central nervous-system signaling rather than direct vascular smooth-muscle action. Bremelanotide is the active ingredient in the FDA-approved prescription drug Vyleesi for a specific female sexual-desire indication; that approval does not make a separate Apex research material an approved drug product.

How It Works

• Melanocortin receptor signaling: Bremelanotide activates central melanocortin pathways involved in arousal and motivated behavior.
• Hypothalamic signaling: Research focuses on brain networks involved in sexual response rather than only peripheral blood flow.
• Neurobehavioral endpoints: Clinical studies have measured desire, distress, arousal, and tolerability outcomes.

Research Areas

• Melanocortin neurobiology
• Sexual-response pathways
• Central nervous-system signaling
• Clinical pharmacology

Research / Study Context

• Phase 3 clinical research: Large randomized trials evaluated efficacy and safety in the FDA-approved indication.
• Earlier male research: Experimental studies also evaluated erectile and arousal-related endpoints in men, but these are not the FDA-approved indication.

Key Research Findings

• Bremelanotide has established central melanocortin pharmacology.
• Its FDA approval is indication- and product-specific.
• Apex should not imply that its RUO material is equivalent to Vyleesi.

Related Research

• Kisspeptin-10
• Selank
• Semax

Scientific Reference Starter Set

• Peptide Education Hub: PT-141/Bremelanotide profile
• FDA prescribing information: Vyleesi (bremelanotide)
• PubMed search: bremelanotide RECONNECT phase 3